Aignostics, a spin-off from Charité – Universitätsmedizin Berlin and the Berlin Institute of Health, pioneering computational pathology for pharmaceutical research and diagnostics, has announced today the closing of €5m in seed round funding.…
CARE (Corona Accelerated R&D in Europe), supported by Europe’s Innovative Medicines Initiative (IMI), is the largest undertaking of its kind dedicated to discovering and developing urgently needed treatment options for COVID-19.
The initiative is…
Myelo Therapeutics GmbH, a clinical-stage pharmaceutical company focused on developing therapies for cancer supportive care and medical countermeasures (MCM), announced today the successful closing of a multi-million Euro financing round, following…
The history of the pharmaceutical company Takeda from Japan has been 239 years, for 39 years
Takeda is active in Germany. During this time it has acquired and developed the current locations in Berlin, Oranienburg, Konstanz and Singen. In…
The development of drugs for the treatment of rare diseases is difficult, as is the development of safe methods of diagnosis. Although the number of patients suffering from rare diseases is relatively large, the estimated 8,000 different rare…
In late January the Sars-Cov-2 pandemic officially arrived and started spreading across Germany. Since then – like in almost every other country globally - every new day feels completely new, uncertain and presents previously unknown challenges,…
At the beginning of 2019, the British foundation Wellcome Trust opened an office in Berlin, thus expanding its activities to Germany. The first project funded by the foundation in Germany is a translation partnership with the Berlin Institute of…
The pharmaceutical company Bayer wants to help turn Berlin into a biotech hub like Boston. This is possible, says head of research Stefan Oelrich in an interview with the Tagesspiegel.
Myelo Therapeutics GmbH, a clinical-stage pharmaceutical company focused on developing therapies for cancer supportive care and medical countermeasures (MCM), announced that it has been awarded a 3-year development contract valued at up to $6…
Repeats of individual building blocks within proteins are the cause of many hereditary diseases, but how such repeats actually cause disease is still largely unknown. Researchers in Berlin investigated how repeat elongations lead to the disease…
